Table 1

Characteristics of primary publications for biological anti-TNFα agents

Reference	Anti-TNFα agent	Trial name	Enrolment start date	Comparator	N	Patient population
Elliott et al 199416	Infliximab	NA	1993	Placebo	72	MTX experienced
Moreland et al 199717	Etanercept	NA	–	Placebo	180	MTX experienced
Maini et al 199818	Infliximab	NA	1994	Placebo	101	MTX experienced
Maini et al 199919	Infliximab	ATTRACT	1997	Placebo	428	MTX experienced
Moreland et al 199920	Etanercept	NA	–	Placebo	234	MTX experienced
Weinblatt et al 199921	Etanercept	NA	–	MTX	89	MTX experienced
Bathon et al 200022	Etanercept	ERA	1997	MTX	632	MTX naive
Kavanaugh et al 200023	Infliximab	NA	1995	Placebo	28	MTX experienced
Choy et al 200224	Certolizumab	NA	–	Placebo	36	MTX experienced
Furst et al 200325	Adalimumab	STAR	2000	Placebo	636	MTX experienced
van de Putte et al 200326	Adalimumab	DE007	2001	Placebo	284	MTX experienced
Weinblatt et al 200327	Adalimumab	ARMADA	–	MTX	271	MTX experienced
Keystone et al 200428	Adalimumab	DE019	2002	MTX	619	MTX experienced
van de Putte et al 200429	Adalimumab	DE011	2000	Placebo	544	MTX experienced
Genovese et al 200430	Etanercept	NA	–	Anakinra	244	MTX experienced
Keystone et al 200431	Etanercept	NA	–	Placebo	420	MTX experienced
Klareskog et al 200432	Etanercept	TEMPO	2000	MTX	652	MTX experienced
Lan et al 200433	Etanercept	NA	2000	Placebo	58	MTX experienced
St. Clair et al 200434	Infliximab	ASPIRE	2000	MTX	1004	MTX naive
Johnsen et al 200635	Etanercept	NA	1999	Etanercept	77	MTX experienced
Abe et al 200636	Infliximab	NA	2000	Placebo	147	MTX experienced
Leirisalo-Repo et al 200637	Infliximab	NEO-RACO	2005	Placebo	99	MTX experienced
Westhovens et al 200638	Infliximab	START	2001	Placebo	1082	MTX experienced
Zhang et al 200639	Infliximab	NA	2003	Placebo	173	MTX experienced
Breedveld et al 200640	Adalimumab	PREMIER	2001	MTX	799	MTX naive
Kim et al 200741	Adalimumab	NA	2003	MTX	128	MTX experienced
Weisman et al 200742	Etanercept	NA	2000	Placebo	535	MTX experienced
Zhou et al 200743	Golimumab	NA	2001	Placebo	36	MTX experienced
Durez et al 200744	Infliximab	NA	2003	MTX and prednisone	44	MTX naive
Fleischmann et al 200845^*	Certolizumab	FAST4WARD	2003	Placebo	220	MTX experienced
Keystone et al 200846	Certolizumab	RAPID1	2005	MTX	982	MTX experienced
Smolen et al 200847^*	Certolizumab	RAPID2	2005	MTX	619	MTX experienced
Combe et al 200848^*	Etanercept	309	2000	SSZ	254	MTX experienced
Emery et al 200849	Etanercept	COMET	2004	MTX	542	MTX naive
Kameda et al 200850	Etanercept	JESMR	2005	MTX	151	MTX experienced
Sheehy et al 200851	Etanercept	NA	–	MTX	40	MTX naive
Wyeth data on file	Etanercept	0881A1-319	2006	MTX	156	MTX experienced
Sennels et al 200852	Etanercept	ADORE	2003	Etanercept	25	MTX experienced
Weinblatt et al 200853	Etanercept	NA	2005	Etanercept	200	MTX experienced
Miyasaka et al 200854	Adalimumab	CHANGE	2004	Placebo	352	MTX experienced
Kay et al 200855	Golimumab	NA	2003	MTX	172	MTX experienced
Keystone 200814	Golimumab	GO–FORWARD	2005	MTX	444	MTX experienced
Emery et al 200915	Golimumab	GO–BEFORE	2005	MTX	634	MTX naive
Smolen et al 200956	Golimumab	GO–AFTER	2006	Placebo	461	MTX experienced

MTX, methotrexate; NA, not available; TNF, tumour necrosis factor.
↵* Date denotes the first date of publication (online)